Phenytoin and postoperative epilepsy
|
|
- Willis Kevin Daniels
- 5 years ago
- Views:
Transcription
1 J Neurosurg 58: , 1983 Phenytoin and postoperative epilepsy A double-blind study J. BRIAN NORTIt, F.R.A.C.S., ROBERT K. PENHALL, F.R.A.C.P., AttMAD HANIEH, F.R.A.C.S., DEREK B. FREWIN, F.R.A.C.P., AND WILLIAM B. TAYLOR, PH.D. Departments of Neurosurgery and Clinical Pharmacology, Royal Adelaide Hospital, and the Department of Statistics, University of A de[aide, Adelaide, South Australia, Australia ~/ A double-blind trial of phenytoin therapy following craniotomy was performed to test the hypothesis that phenytoin is effective in reducing postoperative epilepsy. A significant reduction in the frequency of epilepsy was observed in the group receiving the active drug up to the 10th postoperative week. Half of the seizures occurred in the first 2 weeks and two-thirds within 1 month of cranial surgery. High rates of epilepsy were observed after surgery in patients with meningioma, metastasis, aneurysm, and head injury. Routine prophylaxis with phenytoin (in a dosage of 5 to 6 mg/kg/day) would seem to be indicated, particularly in high-risk patients and, where possible, this treatment should be started 1 week preoperatively. Seizure control is best when therapeutic levels of phenytoin are maintained. KEY WORDS " epilepsy 9 grand mal seizure phenytoin Dilantin epilepsy prophylaxis postoperative epilepsy seizure prophylaxis C LINICAL practice with anti-epileptic prophylaxis after craniotomy varies widely from unit to unit. Despite a large body of evidence suggesting that epilepsy can be minimized, there is no generally accepted pharmacological regimen for postoperative seizure prophylaxis. Since the introduction ofphenytoin in 1938, it has become the most popular anticonvulsant agent because of its efficacy and relative freedom from serious side effects?,11 However, a prospective and randomized study to establish the efficacy of prophylactic postoperative therapy has not yet been reported. 9,12 In an attempt to overcome this, we have conducted a double-blind trial of phenytoin to investigate whether it is effective in reducing postoperative epilepsy. The preliminary results of our investigation have already been published/ Protocol Clinical Material and Methods Patients undergoing a supratentorial operation (burr hole, craniectomy, or osteoplastic flap procedures) at the Royal Adelaide Hospital from January, 1978, to April, 1980, were randomly allocated to receive either phenytoin or an identical placebo. The trial was approved by the Research and Ethics Committee of the Royal Adelaide Hospital. Patients with preoperative epilepsy and those who had previously received any anti-epileptic drug were excluded. Those with cerebral abscess were also excluded because of a strong tendency to epilepsy. 7 Treatment was started in the recovery room with intravenous phenytoin (250 mg twice a day), and then continued with oral medication (100 mg three times a day initially) for 12 months, unless a complication intervened. Serum drug levels were monitored weekly for inpatients, and every 2 months for outpatients, with an enzyme-multiplied immunoassay technique. The drug levels were known only to a clinical pharmacologist, who modified dosage regimens to maintain the phenytoin level within the therapeutic range of 40 to 80 #mol/liter (10 to 20 mg/liter). Blood samples were also obtained from patients on the placebo for "drug monitoring" and "dosage adjustments." If a patient suffered a seizure, a blood sample was taken for determination of the phenytoin level, and the patient was withdrawn from the trial. Placebo-treated patients 672 J. Neurosurg. / Volume 58 / May, 1983
2 Phenytoin and postoperative seizures who developed a seizure were then treated with phenytoin. The data from 281 patients (140 on active medication and 141 on placebo) are presented. Statistical Analysis The results of the present study have been analyzed in accordance with the statistical methodology proposed by Peto, et al., 1~ which is designed for clinical trials that study the length of time to an untoward event. The method was proposed by a group of British and American statisticians, and was developed out of collaborative clinical trials in leukemia and other cancers. They found that the techniques of life table graphs and log-rank p values are accurate, sensitive, and simple ways to interpret the data from such trials. In this analysis, the "survival time" for each of our patients is given as the number of days from randomization at trial inception to the incidence of the first seizure, or to 365 days in the case of seizure-free patients. Other instances of "survival times" of less than 365 days occurred where the patient died or was withdrawn from the trial because of an adverse drug reaction or because of a change of anticonvulsant treatment. Upon experiencing a seizure, the patient was removed from further consideration. The information thus obtained has been subjected to an analysis by actuarial methods to provide estimates of the "survival rates" together with the extent of exposure to risk. The latter forms the basis of risk assessment, since the risk of a seizure at any specified time depends upon the number of seizures observed and the number of patients exposed to risk. The differences between groups were tested by the corrected chi-square test. A probability of less than 5% between groups was accepted as a significant difference. Results This study comprised 281 patients. A more detailed analysis of their group data is presented in Table 1. A total of 44 seizures were observed in the two groups: 18 occurred in the group on active therapy and 26 in the group treated with placebo. Life tables for the active drug, placebo, and combined groups are shown in Table 2 and Fig. 1. The decrease in patients at risk is not strictly compatible with the seizures observed due to departure of individuals from the trial for causes other than epilepsy (Table 1). Therefore, at each seizure time, the estimated percentage of survivors on a life table basis has been calculated, together with the extent of exposure to risk, using the method suggested by Peto, et al.1~ The time relationship between operation and the occurrence of the first seizure is shown in Fig. 2. Eighteen seizures (45%) were observed in the 1st postoperative week, and 28 (64%) in the 1st month. Calculating the total exposure to risk from the life table, we would expect there to be seizures in TABLE 1 Trial data for active drug- and placebo-treated patients Parameter Phenytoin Placebo Group Group no. of cases male:female ratio 1.37:1 1.47:1 age (mean yrs + SD) 46.7 _ no. completing 12 months deaths lost to follow-up review 2 4 medication discontinued 23 7 medication changed 5 18 focal seizures 9 10 generalized seizures 9 16 drug withdrawn due to 12 3 adverse reaction the active drug group and in the placebo group during the 12-month period of the trial. However, we observed 18 patients with epilepsy on active phenytoin treatment and 26 in the placebo group. The chi-square comparison (1.12) of these two groups indicates that the apparent discrepancy between the groups is not significant. In view of this finding, it is unlikely that phenytoin reduces the incidence of epilepsy over the whole 365-day period when the group receiving active drug therapy is considered in its entirety. In our preliminary communication, 8 attention was drawn to the high incidence of epilepsy in the 1st month after surgery. On this basis and considering the apparent rapid fall in survival within the first 30 days after the operation, as evidenced from the combined life table, the exposure to risk over the separate periods of 0 to 30 days and 31 to 365 days has been obtained (Table 3). A significant difference was observed between the active and placebo groups in the first period but not in the second. A further analysis of the efficacy of treatment in relation to postoperative time was obtained by comparing active drug- and placebo-treated groups in terms of seizure incidence at various stages of the 365 days (Table 4). There was no significant difference between the two groups in the first 6 days, but the difference was significant for the period from 7 to 72 days, when the active drug-treated group had a lower incidence of epilepsy. For the period 72 to 365 days, no significant difference was observed between the active and placebo patients, although fewer seizures were observed in the patients on active therapy. Of the 140 patients receiving the active drug, 98 had their dose increased from the initial value of 100 mg three times daily. Seven patients had their dose decreased and 35 patients were not changed. Compliance with therapy (as judged by serum phenytoin levels within the therapeutic range) was seen in 81% of the patients. In those patients completing 12 months in the study, the dosage of phenytoin required to reach therapeutic levels ranged from 3.5 to 6.9 mg/kg (clothed weight)/day, with the average dose for the J. Neurosurg. / Volume 58 / May,
3 J. B. North, et al. TABLE 2 Life table data for the active drug and placebo groups* Phenytoin Group Placebo Group Time Calculated Calculated (days) Seizures No. at Life Table Exposure to Seizures No. at Life Table Exposure to l I l totalseizures * The time (in days) at which seizures occurred during the trial, the number of patients remaining at each time point and their respective exposure to risk are shown. This analysis has been performed using the method of Peto, et al.'~ "" = risk of seizures. group being 5.35 mg/kg/day. Side effects necessitating withdrawal from the trial were seen in 12 patients: eight developed rashes, one involuntary movements, one hirsutism, one headache, and one discomfort of the face. Of the 141 placebo-treated patients, 83 had TABLE 3 Incidence of seizures in the active drug and placebo groups Factor Time Postop (days) phenytoin group seizures observed 8 10 seizures expected placebo group seizures observed 20 6 seizures expected chi-square p value < NS* * NS = not significant. their "dose" increased, while 58 had no change in "medication." It was also interesting to note that three individuals were withdrawn due to "drug-induced" side effects: a rash in one, dizziness in one, and nausea in one. The frequency of seizures observed in the different conditions for which operations were performed is recorded in Table 5. High rates of epilepsy were observed following operations for aneurysm, head injury, and meningioma. When the active and placebo groups were compared in these "high-risk" categories, there was a significantly lower incidence of epilepsy in the active drug group at 30 days and at 343 days (Table 6). However, when patients suffering from metastasis were included in this analysis, the difference at 343 days between the active drug and placebo groups fell below significance (X 2 = 2.51). The 122 patients who completed 12 months on our trial were followed to determine the incidence of seizures during the period of 12 to 24 months after 674 J. Neurosurg. / Volume 58 / May, 1983
4 Phenytoin and postoperative seizures 100-~ 9 Phenytoin 140 Patients Placebo 141 Patients 9 All Patients ;o DAYS FIG. 1. Graph showing postoperative epilepsy in craniotomy from life table data for the subjects who participated in the trial. The horizontal axis has been terminated at 250 days for reasons of scale. No seizures were observed between Days 133 and 209, and none after Day 343. operation, during which time none were receiving anti-epileptic medication. The first seizure occurred in 11 patients during this second 12-month period; seven of these patients had received active phenytoin during the 12 months of the trial and four had been given placebo. Review of the serum phenytoin levels at the time of (days) served Obepilepsy in the 18 patients on active drug therapy 1 2 reveals an interesting trend. Nine of the 18 subjects 3 2 experienced generalized convulsions and eight of these nine had subtherapeutic levels (< 40/~mol/liter 5 4 or 10 mg/liter) of phenytoin. The remaining nine 7 4 patients had focal seizures, and seven of these patients 9 4 had a therapeutic phenytoin level (40 to 80/zmol/liter 13 5 or 10 to 20 mg/liter) at the time of their seizure Discussion 65 9 The data presented in this report substantiate our preliminary finding s that phenytoin significantly re duces the incidence of postcraniotomy epilepsy in comparison with placebo. This protection seems to start at the 7th postoperative day, and continues until about Day 72. The effect of phenytoin is maximal in the 2nd postoperative week (Table 4). TABLE 4 Progressive analysis of data in the active drug and placebo groups* Phenytoin Group Placebo Group Time Postop Seizures Seizures Seizures Seizures Chi- Ex- Ob- Ex- Square pected served pected p Value NS NS NS < < < < < < < NS NS NS NS NS * No seizures were observed after Day 343. NS = not significant. J. Neurosurg. / Volume 58 / May,
5 J. B. North, et al. TABLE 5 Frequency of postoperative epilepsy after various neurosurgical procedures* Phenytoin Placebo Reason for Total Group Group Group Surgery No. % No. % No. % aneurysm 9/ / /27 22 head injury total 17/ / /55 22 with clot 14/ / /40 23 meningioma 4/ / /9 22 metastasis 5/ /6 50 2/7 29 sellar tumor 1 / / /7 glioma 4/ / /16 6 VA shunt 0/25 0/15 0/10 other 4/ / /10 30 * Figures are given as number of patients with epilepsy/number of patients studied. Follow-up period was 12 months. VA = ventriculoatrial. The duration of protection afforded by phenytoin has relevance to the period for which the drug should be given postoperatively. Our data suggest that a period of 2 to 3 months would seem to be a reasonable recommendation, since three-quarters of the seizures had occurred within 3 months (Fig. 2) and a significant reduction in seizures was observed until the 72 to 82 day mark (Table 4). It is somewhat more difficult to make a recommendation from our data as to whether phenytoin should be given for longer periods in patients having operations for aneurysm, head 18 TABLE 6 Analysis of seizure data in high-risk patients* Factor Time Postop (days) phenytoin group seizures observed 5 8 seizures expected placebo group seizures observed seizures expected chi-square p value < 0.05 < 0.05 * High-risk patients included those with aneurysms, head injury, or meningioma. injury, and meningioma (Table 5). The life table analysis used in this series is not well suited to comparing the relatively small subgroups in the "highrisk" patients, but for these a treatment period of 12 months is probably warranted (Table 6). The incidence of seizures in our series is similar to that recorded by others. 1,3-5 Our rates refer to the 12- month period immediately after operation, but this period varies in other series. In our patients receiving placebo, the rates were remarkably similar (22% to 23%) in those patients suffering from aneurysm, head injury, and meningioma. We were surprised at the low incidence (6%) of seizures in the 17 patients with sellar tumors (mainly chromophobe adenoma and craniopharyngioma). This subfrontal operation usually requires retraction of the frontal lobe, but Foy, et al., 4 also recorded a low incidence with this procedure. We did not observe any seizures in patients after >. 16 a_ iii 14 D. w -i- 12 P D ACTIVE PHENYTOIN -]PLACEBO (R 10 P Z P 8 ~L IL O 6 r m :f 4 Z WEEKS POST-OPERATIVE FIG. 2 The time relationship between operation and occurrence of seizures in the active drug and placebo groups. 676 J. Neurosurg. / Volume 58 / May, 1983
6 Phenytoin and postoperative seizures shunting procedures, although Foy, et al., 4 reported a rate of 22% with this operation which they partly explained by the use of Myodil or a Jacques catheter. It has been suggested that a period of anticonvulsant treatment may retard the "maturation" of epileptic foci and therefore that it would have a beneficial effect in the longer term. In other words, the question of interest is whether giving an anticonvulsant agent for a time after craniotomy will result in a reduction in the expected incidence of epilepsy when the administration of the drug is discontinued? Although our trial was not designed to test this hypothesis, we found no support for it; we found a trend for more seizures during the 2nd postoperative year in those patients who had received active phenytoin during the initial 12 months (seven patients) when compared to the placebo group (four patients). We did not find a significant difference in the 1st postoperative week between the incidence of seizures in the phenytoin-treated patients compared to that in patients receiving placebo. We started phenytoin treatment (intravenously) in the recovery room for all cases including elective operations. Phenytoin usually takes 7 to 10 days to reach steady-state kinetics in view of its relatively long half-life. Therefore it would seem appropriate to start phenytoin treatment at least a week before operation when this is feasible, so as to provide adequate cover at the time of surgery. Such a regimen might then be expected to further reduce the incidence of epilepsy in the 1st postoperative week, and this would significantly increase the protection afforded by phenytoin. The dose range of phenytoin of 3.5 to 7 mg/kg/day, which resulted in therapeutic serum levels, is in keeping with the data of others. 6,9 The average dose of 5.35 mg/kg/day was obtained from 37 patients who had completed 12 months of therapy, and who were weighed clothed. The results of the serum phenytoin levels taken at the time of the seizure suggest that patients maintained in the therapeutic range appear to be protected against generalized epilepsy. However, focal seizures did occur in seven of nine patients with a therapeutic phenytoin level. This may suggest that the hydantoins are of somewhat greater value in the prophylaxis against generalized, rather than focal seizures? Conclusions For patients who are to have elective surgery for tumor, aneurysm (including arteriovenous malformation), or head injury, phenytoin should be started 7 to 10 days preoperatively in oral doses of 5 to 6 mg/ kg body weight/day. This period should allow phenytoin to reach a steady state on the day before operation, when the first blood level should be checked, and dosage adjustments made accordingly. In patients who are to have emergency surgery, it would seem appropriate to use an intravenous loading dose of phenytoin (12 mg/kg) in order to achieve an adequate plasma concentration. Phenytoin is continued post- operatively, by the oral route if possible, otherwise intravenously. Blood levels should be monitored weekly for inpatients and every 2 months for outpatients. The length of phenytoin therapy should be 2 to 3 months, but those patients with aneurysm, arteriovenous malformations, head injury, or meningioma should be treated for 12 months. Other factors such as the patients' occupation, prognosis, and likely drug compliance also need consideration in the selection of patients for anti-epileptic therapy and its duration. Patients having shunt operations would not appear to require phenytoin. Acknowledgments We thank Parke Davis Proprietary, Ltd., for their assistance which included supply of phenytoin and placebo medication. Mrs. Alice Grote gave valuable help throughout the trial. We thank Drs. Carney, Reilly, and Simpson for allowing us to study their patients. The Pharmacy Department at the Royal Adelaide Hospital assisted in the conduct of the trial. References 1. Cabral RJ, King TT, Scott DF: Epilepsy after two different neurosurgical approaches to the treatment of ruptured intracranial aneurysm. J Neurol Neurnsurg Psychiatry 39: , Clark PPR: Prevention of postoperative epilepsy. Lancet 1:650, 1980 (Letter) 3. Fabinyi GCA, Artiola-Fortuny L: Epilepsy after craniotomy for intracranial aneurysm. Lancet 1: , 1980 (Letter) 4. Foy PM, Copeland GP, Shaw MDM: The incidence of postoperative seizures. Acta Nenrochir 55: , Gautier-Smith PC: Parasagittal and Falx Menlngiomas. London: Butterworths, 1970, pp Hooper WD, Tyrer JH, Eadie M J: Plasma diphenylhydantoin levels in Australian adults. Anst NZ J Med 4: , Legg N J, Gupta PC, Scott DF: Epilepsy following cerebral abscess. A clinical and EEG study of 70 patients. Brain 96: , North JB, Penhall RK, Hanieh A, et al: Postoperative epilepsy: a double-blind trial of phenytoin after craniotomy. Lancet 1: , Olanow CW, Finn AL: Phenytoin: pharmacokinetics and clinical therapeutics. Nenrosnrgery 8: , Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1-39, Reynolds EH: Drug treatment of epilepsy. Lancet 2: , Royal College of Physicians of London: Clinicopathological conference: Diagnostic difficulties in a case of polypharmacy. Br Med J 1: , 1977 (see Thomas PK, p 216) Manuscript received September 4, Address reprint requests to: J. Brian North, F.R.A.C.S., Department of Neurosurgery, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia 5000, Australia. J. Neurosurg. / Volume 58 / May,
SV2A Ligands: New Antiepileptic Drug for Modern Neurosurgical Consideration!
SV2A Ligands: New Antiepileptic Drug for Modern Neurosurgical Consideration Sorayouth Chumnanvej,M.D. Neurosurgeon Ramathibodi Hospital, Mahidol University Professor Carole Longson, Director of the Health
More informationEpilepsy after two different neurosurgical approaches
Journal ofneurology, Neurosurgery, and Psychiatry, 1976, 39, 1052-1056 Epilepsy after two different neurosurgical approaches to the treatment of ruptured intracranial aneurysm R. J. CABRAL, T. T. KING,
More informationBIBLIOGRAPHIC REFERENCE TABLE FOR SODIUM VALPROATE IN CHILDHOOD EPILEPSY
BIBLIOGRAPHIC REFERENCE TABLE FOR SODIUM VALPROATE IN CHILDHOOD EPILEPSY Bibliographic Marson AG et al. for (Review). The Cochrane 2000 De Silva M et al. Romised or for childhood. Lancet, 1996; 347: 709-713
More informationDouble-blind, placebo controlled, crossover study
448 48ournal of Neurology, Neurosurgery, and Psychiatry 1993;56:448-453 PAPERS Department of Clinical Pharmacology, Queen Elizabeth Hospital, Woodville, SA, G J Schapel Liverpool Hospital, Liverpool, NSW,
More informationTreatment of epilepsy with clonazepam and its effect on other anticonvulsants
Journal of Neurology, Neurosurgery, and Psychiatry, 1977, 4, 538-543 Treatment of epilepsy with clonazepam and its effect on other anticonvulsants R. N. NANDA,1 R. H. JOHNSON,2 H. J. KEOGH, D. G. LAMBIE,
More informationPrognosis of chronic epilepsy with complex partial
Journal of Neurology, Neurosurgery, and Psychiatry 1984;47:1274-1278 279/83 Prognosis of chronic epilepsy with complex partial seizures D SCHMIDT From the Department ofneurology, University of Berlin,
More informationCarbamazepine as a single drug in the treatment of epilepsy A prospective study of serum levels and seizure control
Journal ofneurology, Neurosurgery, and Psychiatry, 1978, 41, 907-912 Carbamazepine as a single drug in the treatment of epilepsy A prospective study of serum levels and seizure control NOEL CALLAGHAN,
More informationRefractory epilepsy: treatment with new antiepileptic drugs
Seizure 2000; 9: 51 57 doi: 10.1053/seiz.1999.0348, available online at http://www.idealibrary.com on Refractory epilepsy: treatment with new antiepileptic drugs P. K. DATTA & P. M. CRAWFORD Department
More informationRisk of seizure recurrence after antiepileptic drug withdrawal, an Indian study
Neurology Asia 2006; 11 : 19 23 Risk of seizure recurrence after antiepileptic drug withdrawal, an Indian study Archana VERMA DM (Neurology) MD, Surendra MISRA DM (Neurology) FRCP (Edin) Department of
More informationCURRICULUM VITAE. SPR in Neurosurgery North Thames Rotation Scheme. 1. Royal Free Hospital RFH ( ; 18 months ) Specialist Registrar
CURRICULUM VITAE Name Title Present Position Address : -Jesus Lafuente : -MD, FRCSEd, PhD : -CONSULTANT NEUROSURGEON : -HOSPÌTAL DEL MAR PASEO MARITIMO 23 BARCELONA 08003 E-mail : jlbspine@gmail.com Phone
More informationPhenytoin versus Levetiracetam for Prevention of Early Posttraumatic Seizures: A Prospective Comparative Study
136 Original Article Phenytoin versus Levetiracetam for Prevention of Early Posttraumatic Seizures: A Prospective Comparative Study Kairav S. Shah 1 Jayun Shah 1 Ponraj K. Sundaram 1 1 Department of Neurosurgery,
More informationEfficacy of postoperative seizure prophylaxis in intra-axial brain tumor resections
J Neurooncol (2014) 118:117 122 DOI 10.1007/s11060-014-1402-9 CLINICAL STUDY Efficacy of postoperative seizure prophylaxis in intra-axial brain tumor resections Shaheryar F. Ansari Bradley N. Bohnstedt
More informationSYNOPSIS INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER (FOR NATIONAL AUTHORITY USE ONLY) Volume: Page:
SYNOPSIS Risperdal Risperidone (R064766) Protocol No.: RIS-USA-150 Part 1 INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER AUTHORITY USE ONLY) Title of Study: A Double-Blind, Placebo-Controlled
More informationShands Jacksonville Department of Pharmacy
Shands Jacksonville Department of Pharmacy Medication Use Evaluation: IV Levetiracetam Evaluation Time Period: 05/27/2013 06/24/2013 Important Aspect of Care: Care of Patients, Medication Use, Prescribing
More informationNew drugs necessity for therapeutic drug monitoring
New drugs necessity for therapeutic drug monitoring Stephan Krähenbühl Clinical Pharmacology & Toxicology University Hospital Basel kraehenbuehl@uhbs.ch Drugs suitable for TDM Narrow therapeutic range
More informationSubject: Cannabidiol (Epidiolex )
09-J3000-08 Original Effective Date: 09/15/18 Reviewed: 08/08/18 Revised: 00/00/00 Next Review: 04/10/19 Subject: Cannabidiol (Epidiolex ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationDr Eddie Mee. Neurosurgeon Auckland City Hospital, Ascot Integrated Hospital, MercyAscot Hospitals, Auckland
Dr Eddie Mee Neurosurgeon Auckland City Hospital, Ascot Integrated Hospital, MercyAscot Hospitals, Auckland 16:30-17:25 WS #48: Current Management of Brain Bleeds and Tumours 17:35-18:30 WS #58: Current
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More informationOutline. What is a seizure? What is epilepsy? Updates in Seizure Management Terminology, Triage & Treatment
Outline Updates in Seizure Management Terminology, Triage & Treatment Joseph Sullivan, MD! Terminology! Videos of different types of seizures! Diagnostic evaluation! Treatment options! Acute! Maintenance
More informationDefinition พ.ญ.ส ธ ดา เย นจ นทร. Epidemiology. Definition 5/25/2016. Seizures after stroke Can we predict? Poststroke seizure
Seizures after stroke Can we predict? พ.ญ.ส ธ ดา เย นจ นทร PMK Epilepsy Annual Meeting 2016 Definition Poststroke seizure : single or multiple convulsive episode(s) after stroke and thought to be related
More informationVO- PMHP Treatment Guideline 102: Electroconvulsive Therapy (ECT)
VO- PMHP Treatment Guideline 102: Electroconvulsive Therapy (ECT) Diagnostic Guidelines: Introduction: Electroconvulsive Therapy has been in continuous use for more than 60 years. The clinical literature
More informationWHOLE LOTTA SHAKIN GOIN ON
WHOLE LOTTA SHAKIN GOIN ON ADAM M. YATES, MD FACEP ASSOCIATE CHIEF OF EMERGENCY SERVICES UPMC MERCY SEIZURE DEFINITIONS Partial(focal) only involves part of the brain General Involves entire brain Simple
More informationPFIZER INC. Study Initiation Date: 15 June 1995; Completion Date: 22 April 1996
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Cerebyx /fosphenytoin
More informationpharmacy, we need to see how clinical pharmacokinetics fits into the pharmaceutical care process.
Therapeutic drug monitoring (TDM) Is a tool that can guide the clinician to provide effective and safe drug therapy in the individual patient. Monitoring can be used to confirm a plasma drug concentration
More informationJournal of Neurology, Neurosurgery, and Psychiatry 1983;46: years. Penry and co-workers, using a similar
Journal of Neurology, Neurosurgery, and Psychiatry 1983;46: 899-904 Low risk of late post-traumatic seizures following severe head injury: implications for clinical trials of prophylaxis JUDITH K McQUEEN,
More informationScottish Medicines Consortium
Scottish Medicines Consortium levetiracetam, 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra ) No. (394/07) UCB Pharma Limited 10 August 2007 The Scottish Medicines Consortium
More informationthe attending radiologist. The patients' medical records and CT scans were reviewed (5) Adverse reactions to previous or subsequent contrast
Journal ofneurology, Neurosurgery, and Psychiatry 1989;52:1170-1175 Seizures after intravenous contrast media for cranial computed tomography MCHAEL NELSON, RCHARD J V BARTLETT, JOHN T LAMB From the General
More informationPFIZER INC. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Cerebyx / Fosphenytoin Sodium
PFIZER INC These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSuccessful re-introduction of lamotrigine after initial rash
Seizure 2000; 9: 282 286 doi: 10.1053/seiz.2000.0394, available online at http://www.idealibrary.com on Successful re-introduction of lamotrigine after initial rash F. M. C. BESAG, G. Y. T. NG & F. POOL
More informationBody position and eerebrospinal fluid pressure. Part 2' Clinical studies on orthostatic pressure and the hydrostatic indifferent point
Body position and eerebrospinal fluid pressure Part 2' Clinical studies on orthostatic pressure and the hydrostatic indifferent point BJORN MAGNAES, M.D. Department of Neurosurgery, Rikshospitalet, Oslo
More informationAND PROPRANOLOL IN HYPERTHYROIDISM
Br. J. clin. Pharmac. (78),,-7 COMPARATIVE TRIAL OF ATENOLOL AND PROPRANOLOL IN HYPERTHYROIDISM D.G. McDEVITT Department of Therapeutics and Pharmacology, The Queen's University, Belfast, Northern Ireland
More informationEfficacy of Levetiracetam: A Review of Three Pivotal Clinical Trials
Epilepsia, 42(Suppl. 4):31 35, 2001 Blackwell Science, Inc. International League Against Epilepsy Efficacy of : A Review of Three Pivotal Clinical Trials Michael Privitera University of Cincinnati Medical
More informationINDIVIDUALVARIATION IN DAILY DOSAGE REQUIREMENTS FOR
Br.J. clin. Pharmac. (1978),,7-71 INDIVIDUALVARIATION IN DAILY DOSAGE REQUIREMENTS FOR PHENYTOIN SODIUM IN PATIENTS WITH EPILEPSY M.H. BAROT & R.H.E. GRANT David Lewis Centre for Epilepsy, Alderley Edge,
More informationAntiepileptics Audit
Antiepileptics Audit Dr Kate Marley Dr Lucy Potter Dr Melanie Brooks Dr Averil Fountain CNS Sue Croft External Reviewer: Dr A Nicolson Consultant Neurologist c CURRENT GUIDANCE 4.1 GENERAL PRINCIPLES Anti-epileptic
More informationPhenytoin intoxication during concurrent diazepam therapy
Journal of Neurology, Neurosurgery, and Psychiatry, 1977, 40, 890-895 Phenytoin intoxication during concurrent diazepam therapy HOWARD J. ROGERS,1 ROBERT A. HASLAM, JAMES LONGSTRETH, AND PAUL S. LIETMAN
More informationlife were assessed on the last three visits. In cases of a seizure an EEG was performed,
474 Neurosurgery L F M Beenen HAMvanAlphen Medical Psychology J Lindeboom F J Snoek Neurology J J Heimans Pharmacy, Academic Hospital Vrije Universiteit, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSurgical management of diastatic linear skull fractures in infants
Surgical management of diastatic linear skull fractures in infants JOHN B. THOMPSON, M.D., THOMAS H. MASON, M.D., GERALD L. HAINES, M.D., AND ROBERT J. CASSIDY, M.D. Divisions of Neurosurgery and Neurology,
More informationWhen to start, which drugs and when to stop
When to start, which drugs and when to stop Dr. Suthida Yenjun, MD. PMK Epilepsy Annual Meeting 2016 The main factors to consider in making the decision The risk for recurrent seizures, which varies based
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 05 May 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 05 May 2010 LAMICTAL 2 mg, dispersible / chewable tablet B/30 (CIP: 354 581-7) LAMICTAL 5 mg, dispersible / chewable
More informationKeywords: treatment; epilepsy; population based cohort Institute of Neurology, University College London, London WC1N 3BG, UK
632 Institute of Neurology, University College London, London WC1N 3BG, UK S D Lhatoo JWASSander S D Shorvon Correspondence to: Professor J W Sander, Department of Clinical and Experimental Epilepsy, Institute
More informationEndovascular Treatment of Cerebral Arteriovenous Malformations. Bs. Nguyễn Ngọc Pi Doanh- Bs Đặng Ngọc Dũng Khoa Ngoại Thần Kinh
Endovascular Treatment of Cerebral Arteriovenous Malformations Bs. Nguyễn Ngọc Pi Doanh- Bs Đặng Ngọc Dũng Khoa Ngoại Thần Kinh Stroke Vascular Malformations of the Brain Epidemiology: - Incidence: 0.1%,
More informationPHENYTOIN DOSING INFORMATION. Adult Dosage
PHENYTOIN DRUGDEX Evaluations DOSING INFORMATION Adult Dosage Normal Dosage Important Note ) Due to the risk of severe hypotension and cardiac arrhythmias, the rate of IV phenytoin administration should
More informationAudit of a monitoring service for free phenytoin
Br. J. clin. Pharmac. (1985), 19, 693-697 Audit of a monitoring service for free phenytoin G. M. PETERSON, S. McLEAN, 2R. J. von WITT & 'K. S. MILLINGEN School of Pharmacy and 'Department of Medicine,
More informationSomnolence and Sedation Were Transient Adverse Events for Most Patients Receiving Clobazam Therapy: Post Hoc Analysis of Trial OV-1012 Data
Elmer ress Short Communication J Neurol Res. 2015;5(4-5):252-256 Somnolence and Sedation Were Transient Adverse Events for Most Patients Receiving Clobazam Therapy: Post Hoc Analysis of Trial OV-1012 Data
More informationINTRACRANIAL ARACHNOID CYSTS: CLASSIFICATION AND MANAGEMENT. G. Tamburrini, Rome
INTRACRANIAL ARACHNOID CYSTS: CLASSIFICATION AND MANAGEMENT G. Tamburrini, Rome Incidence 2% of occasional neuroradiological findings From clinical studies (1960 s): 0.4-1% of intracranial space occupying
More informationIntervention [5] Comparison [6]
Cowan LD. The epidemiology of the epilepsies in children. Mental Retardation and Developmental Disabilities Res Reviews, 2002; 8: 171-181 Review article Paediatric patients Discusses incidence and prevalence
More informationmg 25 mg mg 25 mg mg 100 mg 1
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationQ9. In adults and children with convulsive epilepsy in remission, when should treatment be discontinued?
updated 2012 When to discontinue antiepileptic drug treatment in adults and children Q9. In adults and children with convulsive epilepsy in remission, when should treatment be discontinued? Background
More informationSYNOPSIS. Clinical Study Report IM Double-blind Period
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier SYNOPSIS (For National Authority
More informationDownloaded from by guest on August 19, 2018
Pediatrics VOLUME 25 JANUARY 1960 NUMBER 1 AMERICAN ACADEMY OF PEDIATRICS PROCEEDINGS ABDOMINAL EPILEPSY IN CHILDHOOD George H. Schade, M.D., and Helen Gofman, M.D. Department of Pediatrics and Mental
More informationSupratentorial cerebral arteriovenous malformations : a clinical analysis
Original article: Supratentorial cerebral arteriovenous malformations : a clinical analysis Dr. Rajneesh Gour 1, Dr. S. N. Ghosh 2, Dr. Sumit Deb 3 1Dept.Of Surgery,Chirayu Medical College & Research Centre,
More informationAdjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes
Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes Brian Hardy, PharmD, FCSHP, FCCP Coordinator Education and Clinical Programs Department of Pharmacy Sunnybrook
More informationPROPHYLACTIC ANTICONVULSANT THERAPY
PROPHYLACTIC ANTICONVULSANT THERAPY Dr. Khalid Siddiqui FRCSC, ABNS, FAANS Consultant Neurosurgery Assistant Medical Director Dr Sulaiman Alhabib Medical Group, Al-Rayan PAPNS 2015 11/24/2015 1 Introduction
More informationThe role of prophylactic anticonvulsants in moderate to severe head injury
Int J Emerg Med (2010) 3:187 191 DOI 10.1007/s12245-010-0180-1 REVIEW ARTICLE The role of prophylactic anticonvulsants in moderate to severe head injury Arshad Ali Khan & Ashis Banerjee Received: 18 December
More informationF OR several years we have used a linear. Limited exposure in cerebral surgery. Technical note. trephine aid drill. Technique
Technical note DONALD H. WILSON, M.D. Section o/ Neurosurgery, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire ~' A limited exposure is possible, and perhaps preferable, for most cerebral surgery.
More informationSEIZURE OUTCOME AFTER EPILEPSY SURGERY
SEIZURE OUTCOME AFTER EPILEPSY SURGERY Prakash Kotagal, M.D. Head, Pediatric Epilepsy Cleveland Clinic Epilepsy Center LEFT TEMPORAL LOBE ASTROCYTOMA SEIZURE OUTCOME 1 YEAR AFTER EPILEPSY SURGERY IN ADULTS
More informationeslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd
eslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd 8 October 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationDavid Dredge, MD MGH Child Neurology CME Course September 9, 2017
David Dredge, MD MGH Child Neurology CME Course September 9, 2017 } 25-40,000 children experience their first nonfebrile seizure each year } AAN/CNS guidelines developed in early 2000s and subsequently
More information2. SYNOPSIS Name of Sponsor/Company:
in patients with refractory partial seizures 14 Jun 2007 2. SYNOPSIS TITLE OF STUDY: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomized,
More informationDeep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H
Deep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H Authors' objectives To systematically review the incidence of deep vein
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationMeningioma The Sarawak General Hospital Experience
ORIGI.NAL ARTICLE Meningioma The Sarawak General Hospital Experience S H Wong, FRACS, S H Chan, MBBS Hospital Umum Sarawak, Jalan Tun Ahmad Zaidi Adruce, Kuching, 986 Sarawak Introduction Meningioma is
More informationUse Of Tenoxicam For Post Craniotomy Pain Relief With Or Without Bupivacaine Scalp Infiltration: A Randomized Study
ISPUB.COM The Internet Journal of Anesthesiology Volume 15 Number 2 Use Of Tenoxicam For Post Craniotomy Pain Relief With Or Without Bupivacaine Scalp Infiltration: A Randomized Study A El-Dawlatly, S
More informationSymptoms and problems in the End of Life Phase of High Grade Glioma Patients
Chapter 2.1 Symptoms and problems in the End of Life Phase of High Grade Glioma Patients Eefje M. Sizoo Lies Braam Tjeerd J. Postma H. Roeline W. Pasman Jan J. Heimans Martin Klein Jaap C. Reijneveld Martin
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationOn completion of this chapter you should be able to: list the most common types of childhood epilepsies and their symptoms
9 Epilepsy The incidence of epilepsy is highest in the first two decades of life. It falls after that only to rise again in late life. Epilepsy is one of the most common chronic neurological condition
More informationSafety and Efficacy of Oxcarbazepine: Results of Randomized, Double-Blind Trials
Safety and Efficacy of Oxcarbazepine: Results of Randomized, Double-Blind Trials Ahmad Beydoun, M.D. Oxcarbazepine is approved as monotherapy and adjunctive therapy for partial seizures with and without
More informationMERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES
MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines
More informationMedical Policy Original Effective Date: Revised Date: Page 1 of 5
Disclaimer Description Coverage Determination Refer to the member s specific benefit plan and Schedule of Benefits to determine coverage. This may not be a benefit on all plans or the plan may have broader
More informationLondon, 07 August 2006 Product name: Keppra Procedure No. EMEA/H/C/277/II/63 SCIENTIFIC DISCUSSION
London, 07 August 2006 Product name: Keppra Procedure No. EMEA/H/C/277/II/63 SCIENTIFIC DISCUSSION 1/15 EMEA 2006 1. Introduction Epilepsy is one of the most common and challenging neurological disorders.
More informationAdjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options
Seizure 1995: 4:37-44 Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options B.A. O'NEILL, M.R. TRIMBLE* & D.S. BLOOM Arthur D. Little Ltd, Berkley Square House,
More informationGabapentin as an antiepileptic drug in man
Journal of Neurology, Neurosurgery, and Psychiatry 1987;50:682-686 Gabapentin as an antiepileptic drug in man P CRAWFORD, E GHADAL, R LANE, L BLUMHARDT, D CHADWCK From the Department ofneurology, Walton
More informationAnticholinergic withdrawal and benzhexol treatment
Journal of Neurology, Neurosurgery, and Psychiatry, 1973, 36, 936-941 Anticholinergic withdrawal and benzhexol treatment in Parkion's disease P. M. HORROCKS, D. J. VICARY, J. E. REES, J. D. PARKES, AND
More informationBACKGROUND AND SCIENTIFIC RATIONALE. Protocol Code: ISRCTN V 1.0 date 30 Jan 2012
BACKGROUND AND SCIENTIFIC RATIONALE Protocol Code: ISRCTN15088122 V 1.0 date 30 Jan 2012 Traumatic Brain Injury 10 million killed or hospitalised every year 90% in low and middle income countries Mostly
More informationBackground. Correlation between epilepsy and attention deficit hyperactivity disorder. Background. Epidemiology of ADHD among children with epilepsy
Correlation between epilepsy and attention deficit hyperactivity disorder I-Ching Chou M.D. Director, Department of Pediatric Neurology China Medical University Hospital Taiwan Background Attention deficit/hyperactivity
More informationUrate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout
Philippine Journal of Internal Medicine Meta-Analysis Urate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout Erika Bianca S. Villazor-Isidro, M.D.*; John Carlo G.
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSeizures in high-grade glioma patients:
Seizures in high-grade glioma patients: a serious challenge in the end of life phase JAF Koekkoek,* EM Sizoo,* TJ Postma, JJ Heimans, HRW Pasman, L Deliens, MJB Taphoorn and JC Reijneveld BMJ Support Palliat
More information4. GUIDELINES FOR THE USE OF ANTI- EPILEPTICS IN PALLIATIVE CARE
4. GUIDELINES FOR THE USE OF ANTI- EPILEPTICS IN PALLIATIVE CARE 4.1 GENERAL PRINCIPLES Anti-epileptic drugs should be considered in all patients with primary or secondary brain tumours who have a history
More informationby severe excercise, an accepted method for In addition, practolol had a proportionately larger effect on exc6rcise tachycardia than it had on
Br. J. clin. Pharmac. (1975), 2, 411-416 COMPARATIVE TRIAL OF PROPRANOLOL AND PRACTOLOL IN J.K. NELSON The Ulster Hospital, Dundonald, Belfast, N. Ireland HYPERTHYROIDISM D.G. McDEVITT Department of Therapeutics
More informationRefractory Seizures. Dr James Edwards EMCORE May 30th 2014
Refractory Seizures Dr James Edwards EMCORE May 30th 2014 Refractory Seizures Seizures are a common presentation to the ED and some patients will have multiple seizures or have a reduced level of consciousness
More informationOriginal Article. Emergency Department Evaluation of Ventricular Shunt Malfunction. Is the Shunt Series Really Necessary? Raymond Pitetti, MD, MPH
Original Article Emergency Department Evaluation of Ventricular Shunt Malfunction Is the Shunt Series Really Necessary? Raymond Pitetti, MD, MPH Objective: The malfunction of a ventricular shunt is one
More informationVIMPAT. General information and Dosage Guide. When you need more than your current therapy. Funding criteria applies
VIMPAT General information and Dosage Guide VIMPAT Tablets (lacosamide).vimpat is a funded prescription medicine for patients that meet special medical criteria. Normal doctor s fees and pharmacy charges
More informationManagement of the Fitting Child. Dr Mergan Naidoo
Management of the Fitting Child Dr Mergan Naidoo Seizures A seizure is a change in movement, attention or level of awareness that is sustained or repetitive and occurs as a result of abnormal neuronal
More informationGEORGE E. PERRET, M.D., AND CARL J. GRAF, M.D.
J Neurosurg 47:590-595, 1977 Subgaleal shunt for temporary ventricle decompression and subdural drainage GEORGE E. PERRET, M.D., AND CARL J. GRAF, M.D. Division of Neurological Surgery, University of Iowa
More informationACTH therapy for generalized seizures other than spasms
Seizure (2006) 15, 469 475 www.elsevier.com/locate/yseiz ACTH therapy for generalized seizures other than spasms Akihisa Okumura a,b, *, Takeshi Tsuji b, Toru Kato b, Jun Natsume b, Tamiko Negoro b, Kazuyoshi
More informationSynopsis (C1034T02) CNTO 95 Module 5.3 Clinical Study Report C1034T02
Module 5.3 Protocol: EudraCT No.: 2004-002130-18 Title of the study: A Phase 1/2, Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human
More informationModified Atkins diet in adult with refractory epilepsy: A controlled randomized clinical trial
Iranian Journal of Neurology Original Paper Iran J Neurol 2017; 16(2): 72-7 Modified Atkins diet in adult with refractory epilepsy: A controlled randomized clinical trial Received: 17 Dec. 2016 Accepted:
More informationTherapeutic drug monitoring in epilepsy treatment
Therapeutic drug monitoring in epilepsy treatment Published Jun 24, 1998 Version 1 Findings by SBU Alert Drug monitoring as a means to adapt the dosage of antiepileptic drugs to achieve a particular concentration
More informationTRANSPARENCY COMMITTEE OPINION. 19 July 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 July 2006 Keppra 250 mg, film-coated tablets Box of 60 tablets (CIP code: 356 013-6) Keppra 500 mg, film-coated
More informationMultimodal Imaging in Extratemporal Epilepsy Surgery
Open Access Case Report DOI: 10.7759/cureus.2338 Multimodal Imaging in Extratemporal Epilepsy Surgery Christian Vollmar 1, Aurelia Peraud 2, Soheyl Noachtar 1 1. Epilepsy Center, Dept. of Neurology, University
More informationNeurosurgery. Neurosurgery
Neurosurgery Neurosurgery Neurosurgery Telephone Numbers: Appointment: 202-476-3020 Fax: 202-476-3091 Administration: 202-476-3020 Evenings and Weekends: 202-476-5000 Robert Keating, MD, Chief The Division
More informationPsychomotor Epilepsy in Childhood
for all. Its very emergency nature may at times add trouble since the tendency may be to overdose. It should be kept in mind that harm can be done by overtreating a patient in status epilepticus, particularly
More informationCharacteristics of Headache Associated with Intractable Partial Epilepsy
Epilepsia, 46(8):1241 1245, 2005 Blackwell Publishing, Inc. C 2005 International League Against Epilepsy Characteristics of Headache Associated with Intractable Partial Epilepsy Alexei E. Yankovsky, Frederick
More informationPFIZER INC. Study Initiation Date and Completion Dates: Information not available (Date of Statistical Report: 16 May 2004)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSuitable dose and duration of fluvoxamine administration to treat depression
PCN Psychiatric and Clinical Neurosciences 1323-13162003 Blackwell Science Pty Ltd 572April 2003 1098 Dose and duration of fluvoxamine S. Morishita and S. Arita 10.1046/j.1323-1316.2002.01098.x Original
More informationLate Onset Shake-Etiology At Stake - A Prospective Study
Original Article Late Onset Shake-Etiology At Stake - A Prospective Study G Sendil 1, Arun N Kumar 1, Mohan V Kumar 2 1 Senior Resident, ESIC PGIMSR & MH, Bangalore, 2 Consultant Physician Columbia Asia
More information